News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(USGovernment-News.Com, August 07, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies Implant Sciences (IMSC) as a key play for the month of August as a pivotal milestone has the potential to launch the company into the mainstream of homeland defense and airport security.
Numerous reports have indicated over the past couple of quarters that the TSA would be due in August to announce its decision. Recently-broadcast key media coverage provides an indication that the company is ramping up production in plans for a positive approval decision, all the while foreign orders have also been rolling in as the company diversifies its revenue base.
Additional clues have been provided by Implant indicating success, namely with the amount of key new hirings that have been announced over the duration of 2012 thus far. Any company planning for expansion and a move to the mainstream would be expected to grow, but what is significant about Implant's new additions are that some were convinced to move to Implant from competing companies and have long resume sheets that include big players in the sector such as GE Security (GE) and Safran's Morpho Detection. The list of new hires and advisers also have deep connections to the US Departments of State and Homeland Defense.
The validation provided investors by the new team members has helped to boost investor confidence enough to spark a general surge in the IMSC share price, which has tripled already at points this year. Because a positive decision by the TSA later this month would open the door for Implant to land immediate government contracts, namely in line with a December 3 mandate by the TSA that will require all inbound-US air cargo on passenger airlines to be screened for explosives, additional share price moves could be in store.
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
